James S Blachly, MD
James S Blachly, MD
Assistant Professor of Internal Medicine, The Ohio State University
Geverifieerd e-mailadres voor osumc.edu
Geciteerd door
Geciteerd door
Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL
JA Woyach, AS Ruppert, NA Heerema, W Zhao, AM Booth, W Ding, ...
New England Journal of Medicine, 2018
BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia
JA Woyach, AS Ruppert, D Guinn, A Lehman, JS Blachly, A Lozanski, ...
Journal of Clinical Oncology 35 (13), 1437, 2017
Expression and prognostic impact of lncRNAs in acute myeloid leukemia
R Garzon, S Volinia, D Papaioannou, D Nicolet, J Kohlschmidt, PS Yan, ...
Proceedings of the National Academy of Sciences 111 (52), 18679-18684, 2014
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia
MR Grever, O Abdel-Wahab, LA Andritsos, V Banerji, J Barrientos, ...
Blood, The Journal of the American Society of Hematology 129 (5), 553-560, 2017
Targeting PI 3‐kinase (PI 3 K), AKT and m TOR axis in lymphoma
JS Blachly, RA Baiocchi
British journal of haematology 167 (1), 19-32, 2014
Emerging drug profile: cyclin-dependent kinase inhibitors
JS Blachly, JC Byrd
Leukemia & lymphoma 54 (10), 2133-2143, 2013
BRD4 profiling identifies critical chronic lymphocytic leukemia oncogenic circuits and reveals sensitivity to PLX51107, a novel structurally distinct BET inhibitor
HG Ozer, D El-Gamal, B Powell, ZA Hing, JS Blachly, B Harrington, ...
Cancer discovery 8 (4), 458-477, 2018
Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia
B Bhatnagar, AK Eisfeld, D Nicolet, K Mrózek, JS Blachly, S Orwick, ...
British journal of haematology 175 (2), 226-236, 2016
HDAC inhibition induces microRNA-182, which targets RAD51 and impairs HR repair to sensitize cells to sapacitabine in acute myelogenous leukemia
TH Lai, B Ewald, A Zecevic, C Liu, M Sulda, D Papaioannou, R Garzon, ...
Clinical cancer research 22 (14), 3537-3549, 2016
Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies
AK Eisfeld, J Kohlschmidt, K Mrózek, JS Blachly, CJ Walker, D Nicolet, ...
Leukemia 32 (6), 1338-1348, 2018
PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL
D El-Gamal, K Williams, TD LaFollette, M Cannon, JS Blachly, Y Zhong, ...
Blood 124 (9), 1481-1491, 2014
Quality Control for RNA-Seq (QuaCRS): an integrated quality control pipeline
KW Kroll, NE Mokaram, AR Pelletier, DE Frankhouser, MS Westphal, ...
Cancer informatics 13, CIN. S14022, 2014
The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia
AK Eisfeld, K Mrózek, J Kohlschmidt, D Nicolet, S Orwick, CJ Walker, ...
Leukemia 31 (10), 2211-2218, 2017
Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia
JS Blachly, AS Ruppert, W Zhao, S Long, J Flynn, I Flinn, J Jones, ...
Proceedings of the National Academy of Sciences 112 (14), 4322-4327, 2015
EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia
E Young, D Noerenberg, L Mansouri, V Ljungström, M Frick, LA Sutton, ...
Leukemia 31 (7), 1547-1554, 2017
Hairy cell leukemia: update on molecular profiling and therapeutic advances
MR Grever, JS Blachly, LA Andritsos
Blood reviews 28 (5), 197-203, 2014
Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t (8; 21)(q22; q22) acute myeloid leukemia
AK Eisfeld, J Kohlschmidt, S Schwind, D Nicolet, JS Blachly, S Orwick, ...
Leukemia 31 (6), 1278-1285, 2017
Incidence and type of opportunistic infections during ibrutinib treatment at a single academic center
KA Rogers, M Luay, Q Zhao, T Wiczer, L Levine, EB Zeinab, JS Blachly, ...
Blood 130 (Supplement 1), 830-830, 2017
Cotreatment of hairy cell leukemia and melanoma with the BRAF inhibitor dabrafenib
JS Blachly, G Lozanski, DM Lucas, MR Grever, K Kendra, LA Andritsos
Journal of the National Comprehensive Cancer Network 13 (1), 9-13, 2015
Targeting BTK through microRNA in chronic lymphocytic leukemia
A Bottoni, L Rizzotto, TH Lai, C Liu, LL Smith, R Mantel, S Reiff, ...
Blood, The Journal of the American Society of Hematology 128 (26), 3101-3112, 2016
Het systeem kan de bewerking nu niet uitvoeren. Probeer het later opnieuw.
Artikelen 1–20